UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1332-7
Program Prior Authorization/Notification: Diabetes Medications – GLP-1 & Dual
GIP/GLP-1 Receptor Agonists
Medication Bydureon BCise (exenatide extended-release), Byetta (exenatide),
Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (semaglutide),
Trulicity (dulaglutide), Victoza (liraglutide)*
P&T Approval Date 10/2020, 11/2021, 9/2022, 5/2023, 4/2024, 4/2025
Effective Date 7/1/2025
1. Background:
Byetta (exenatide), Ozempic (semaglutide), and Rybelsus (semaglutide) are indicated as an
adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Bydureon BCise (exenatide extended-release), Trulicity (dulaglutide) and Victoza (liraglutide)*
are indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years
of age and older with type 2 diabetes mellitus. Ozempic, Trulicity and Victoza* are also
indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-
fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and
established cardiovascular disease. Finally, Ozempic carries an additional indication to reduce
the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults
with type 2 diabetes mellitus and chronic kidney disease.
Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and
glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to
improve glycemic control in adults with type 2 diabetes mellitus.
Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity and Victoza* are only
indicated for the treatment of type 2 DM and are not FDA approved for the treatment of weight
loss.
2. Coverage Criteriaa, b:
A. Authorization
1. Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity or Victoza will be
approved based on one the following criteria:
a. Submission of medical records (e.g., chart notes) confirming diagnosis of type 2 diabetes
mellitus as evidenced by one of the following laboratory values
1) A1C greater than or equal to 6.5%
2) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL
3) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during oral glucose
tolerance test
© 2025 UnitedHealthcare Services, Inc.
1
4) Random plasma glucose >/= 200 mg/dL in patient with classic symptoms of
hyperglycemia or hyperglycemic crisis
-OR-
b. For patients requiring ongoing treatment for type 2 diabetes mellitus (i.e., diagnosed
greater than 2 years ago), submission of medical records (e.g. chart notes) confirming
diagnosis of type 2 diabetes mellitus
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
b Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza are not FDA approved
for the treatment of weight loss. Medications used for the purposes of weight loss are typically
excluded from benefit coverage. Coverage is determined by the member’s prescription drug
benefit plan.
Authorization will be issued for 12 months.
Brand Victoza is typically excluded from coverage.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Byetta [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2024.
2. Bydureon BCise [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November
2024.
3. Mounjaro [package insert] Indianapolis, IN: Eli Lilly and Company; November 2024.
4. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; January 2025.
5. Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; December2024.
6. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; November 2024.
7. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; February 2025.
8. American Diabetes Association. Standard of Medical Care in Diabetes - 2025. Diabetes Care
2025;48 (Supplement 1).
9. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a
Diabetes Mellitus Comprehensive Care Plan - 2022 Update. AACE Clinical Practice Guidelines.
Endocr Pract. 2022;28: 923-1049
Program Prior Authorization/Notification: Diabetes Medications – GLP-1
Receptor Agonists
Change Control
10/2020 New program.
© 2025 UnitedHealthcare Services, Inc.
2
3/2021 Administrative change to adjust Oxford effective date.
11/2021 Annual review. Updated references.
9/2022 Updated criteria to define accepted laboratory testing methodologies per
treatment guidelines for diagnosis of diabetes and use is not solely for
weight loss. Updated references. Added state mandate footnote.
5/2023 Review. Removed Adlyxin & Bydureon. Added Mounjaro. Added
medical record requirement for diagnosis of type 2 diabetes. Separated
criteria for existing and new diagnosis for diabetes.
4/2024 Added additional laboratory value. Removed that step therapy may be
in place. Updated references.
4/2025 Annual review – updated background and references.
© 2025 UnitedHealthcare Services, Inc.
3